secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028771
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q3 2022 net loss $12.0M; $137.9M cash; OV329 Phase 1 to start Q4
--------------------------------------------------------------------------------

- Net loss of $12.0M ($0.17 per share) vs $11.4M loss in Q3 2021; R&D expense $5.2M.
- Cash, cash equivalents and marketable securities totaled $137.9M as of Sept 30, 2022.
- FDA cleared IND for OV329; Phase 1 trial in healthy volunteers planned for Q4 2022.
- Executed additional $3.5M investment in Gensaic convertible preferred stock for gene delivery platform.
- Takeda continues pivotal Phase 3 trials for soticlestat; Ovid eligible for up to $660M milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/0001628280-22-028771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/ovid-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer